
Endari for the Treatment of Sickle Cell Disease
Endari™ is an orally administered powdered form of amino acid L-glutamine indicated for the treatment of sickle-cell disease.
GlycoMar is an innovative biotechnology company simultaneously developing marine natural products for the pharmaceutical, cosmeceutical, and nutraceutical markets.
GlycoMar is an innovative biotechnology company simultaneously developing marine natural products for the pharmaceutical, cosmeceutical, and nutraceutical markets.
GlycoMar distinguishes itself from other biotechnology companies by focusing on marine glycobiology – giving it unique access to a class of proprietary novel molecules with invaluable biological profiles. GlycoMar also offers a range of complementary contract research services, giving customers access to its range of bespoke anti-inflammatory screening assays and glycobiology analytical tools.
GlycoMar is uniquely focused on the development of novel therapies based on saccharide molecules from marine organisms. These molecules offer a unique therapeutic approach with an excellent safety profile. The company has developed a unique library of polysaccharides and glycosaminoglycans. The molecules have been the subject of compositional analysis and partial structural characterisation. Anti-inflammatory screening has shown a high hit rate of valuable activity, which is being developed for respiratory inflammatory disease in collaboration with a pharmaceutical partner.
GlycoMar is seeking partners interested in other therapeutic areas, including anti-inflammatory, anti-cancer, anti-coagulant, and anti-infective.
GlycoMar has developed processes for the production of novel active saccharides from unicellular marine microalgae. These products are sustainably produced from naturally occurring marine microalgae. They have the following properties which can support a wide range of claims:
GlycoMar’s nutraceutical and cosmeceutical ingredients compare very favourably with existing saccharide products from botanical or animal sources.
GlycoMar’s specialist screening facility has been established to provide flexible in vitro screening services to a wide range of organisations involved in therapeutic discovery. GlycoMar offers a suite of cost-effective primary screens, using cells from healthy human donor volunteers and cell lines.
Screening assays (marker and cell type):
GlycoMar’s specialist analytical laboratory has been established to provide compositional analysis of saccharide molecules, including glycosaminoglycans. We can also offer full structural analysis of GAGs by NMR.
Analytical services:
Endari™ is an orally administered powdered form of amino acid L-glutamine indicated for the treatment of sickle-cell disease.
Thank you for submitting the form. Your enquiry will be submitted to the company.